Abbott To Assert New Biaxin XL Patent In Ongoing Suits
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott is asserting its new pharmacokinetic patent issued for Biaxin XL (clarithromycin extended-release) in ongoing litigation, the company said during its earnings call April 12
You may also be interested in...
Teva’s Biaxin XL Generic Barred From Launch Pending May 26 Hearing
A temporary restraining order prevents Teva from launching its extended-release generic upon the May 23 expiration of the clarithromycin compound patent. Abbott already has gotten a jump on potential generic versions of immediate-release Biaxin with an “authorized” generic sold through Dava.
Teva’s Biaxin XL Generic Barred From Launch Pending May 26 Hearing
A temporary restraining order prevents Teva from launching its extended-release generic upon the May 23 expiration of the clarithromycin compound patent. Abbott already has gotten a jump on potential generic versions of immediate-release Biaxin with an “authorized” generic sold through Dava.
Abbott To Bolster Biaxin XL Patent Protection Ahead Of Compound Expiration In May
The additional intellectual property for the extended-release formulation will give generic firms “something to think about,” Abbott CFO Freyman says at SG Cowen investor conference. Abbott says it filed suit against three generic manufacturers March 14.